Sokolyuk T. Application of diacamph for the correction of basic metabolic syndrome components: Experimental justification

It has been well-proven that, applied in a dose 50 % less than that of metformin, diacamph brakes metabolic presentations of insulin resistance syndrome for rats at the stage of pre-diabetes, the fact which is testified as follows: insulin susceptibility enhancement, improvement of tolerance to carbonhydrates, reduction of body mass increase rate, retrogression of free fatty acids level in the blood serum, pentose-phosphate pathway intensity growth, gluconeogenesis inhibition, suppression of initial non-enzimatic glycosilation reactions, oxidative stress relief. It has been established that application of diacamph in the abovementioned dose, results in substantial lipid and carbohydrate metabolism improvement, reduction of lipid peroxidation primary products level as well as increase in antioxidant protection system activity level among rats with diabetes metabolic syndrome (relative insulin deficiency). Besides, the study has identified positive influence of diacamph on glucose homoeostasis, lipid profile, oxidative stress, hypertension and cardiovascular fitness in the presence of diabetes mellitus metabolic syndrome (absolute insulin deficiency).